Given the variability in the distribution and function of HIF subtypes across renal cells, prolonged administration of HIF-PHI may result in the accumulation of HIF-1α, which could lead to adverse outcomes such as renal fibrosis, pathological angiogenesis, vascular calcification, and the promotion of tumorigenesis. This evidence concerns the gene HIF1A and renal fibrosis.